76 related articles for article (PubMed ID: 29095060)
1. Emerging molecular predictive and prognostic factors in acute myeloid leukemia.
McCurdy SR; Levis MJ
Leuk Lymphoma; 2018 Sep; 59(9):2021-2039. PubMed ID: 29095060
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies.
Ripperger T; Tawana K; Kratz C; Schlegelberger B; Fitzgibbon J; Steinemann D
Eur J Hum Genet; 2016 Aug; 24(8):. PubMed ID: 26813945
[No Abstract] [Full Text] [Related]
3. Molecular testing for acute myeloid leukemia.
Qin D
Cancer Biol Med; 2021 Aug; 19(1):4-13. PubMed ID: 34347394
[TBL] [Abstract][Full Text] [Related]
4. First Approved Kinase Inhibitor for AML.
Rasko JEJ; Hughes TP
Cell; 2017 Nov; 171(5):981. PubMed ID: 29149610
[TBL] [Abstract][Full Text] [Related]
5. The importance of FLT3 mutational analysis in acute myeloid leukemia.
Patnaik MM
Leuk Lymphoma; 2018 Oct; 59(10):2273-2286. PubMed ID: 29164965
[TBL] [Abstract][Full Text] [Related]
6. State of the Art Update and Next Questions: Acute Myeloid Leukemia.
Sweet K; Lancet J
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):703-709. PubMed ID: 29110833
[TBL] [Abstract][Full Text] [Related]
7. AML in 2017: Advances in clinical practice.
Rowe JM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):283-286. PubMed ID: 29156195
[TBL] [Abstract][Full Text] [Related]
8. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
9. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Sahoo RK; Kumar L
N Engl J Med; 2017 Nov; 377(19):1901-2. PubMed ID: 29120133
[No Abstract] [Full Text] [Related]
10. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Altman JK; Foran JM; Pratz KW; Trone D; Cortes JE; Tallman MS
Am J Hematol; 2018 Feb; 93(2):213-221. PubMed ID: 29139135
[TBL] [Abstract][Full Text] [Related]
11. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.
Medeiros BC; McCaul K; Kambhampati S; Pollyea DA; Kumar R; Silverman LR; Kew A; Saini L; Beach CL; Vij R; Wang X; Zhong J; Gale RP
Haematologica; 2018 Jan; 103(1):101-106. PubMed ID: 29097499
[TBL] [Abstract][Full Text] [Related]
13. A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells.
Espadinha AS; Prouzet-Mauléon V; Claverol S; Lagarde V; Bonneu M; Mahon FX; Cardinaud B
Oncotarget; 2017 Sep; 8(44):76174-76188. PubMed ID: 29100302
[TBL] [Abstract][Full Text] [Related]
14. The More, The Better: "Do the Right Thing" For Natural Killer Immunotherapy in Acute Myeloid Leukemia.
Parisi S; Lecciso M; Ocadlikova D; Salvestrini V; Ciciarello M; Forte D; Corradi G; Cavo M; Curti A
Front Immunol; 2017; 8():1330. PubMed ID: 29097997
[TBL] [Abstract][Full Text] [Related]
15. Advances in targeted therapy for acute myeloid leukaemia.
Kayser S; Levis MJ
Br J Haematol; 2018 Feb; 180(4):484-500. PubMed ID: 29193012
[TBL] [Abstract][Full Text] [Related]
16. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.
O'Connor D; Enshaei A; Bartram J; Hancock J; Harrison CJ; Hough R; Samarasinghe S; Schwab C; Vora A; Wade R; Moppett J; Moorman AV; Goulden N
J Clin Oncol; 2018 Jan; 36(1):34-43. PubMed ID: 29131699
[TBL] [Abstract][Full Text] [Related]
17. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Eskazan AE
N Engl J Med; 2017 Nov; 377(19):1901. PubMed ID: 29120132
[No Abstract] [Full Text] [Related]
18. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
[TBL] [Abstract][Full Text] [Related]
19. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
[TBL] [Abstract][Full Text] [Related]
20. Multiplex fusion gene testing in pediatric acute myeloid leukemia.
Iijima-Yamashita Y; Matsuo H; Yamada M; Deguchi T; Kiyokawa N; Shimada A; Tawa A; Takahashi H; Tomizawa D; Taga T; Kinoshita A; Adachi S; Horibe K
Pediatr Int; 2018 Jan; 60(1):47-51. PubMed ID: 29105243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
